# Rezpegaldesleukin PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/rezpegaldesleukin

> The next catalyst for rezpegaldesleukin, sponsored by NEKTAR THERAPEUTICS (NKTR), is its trial start, Dec 2026.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, half-year only, year only, exact day, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | rezpegaldesleukin |
| Codes | NKTR-358, NKRT-358 |
| Sponsor | NEKTAR THERAPEUTICS (NKTR) https://sec-api.dev/companies/nktr/catalysts |
| Indications | [moderate-to-severe atopic dermatitis](https://sec-api.dev/indications/moderate-to-severe-atopic-dermatitis), [severe-to-very severe alopecia areata](https://sec-api.dev/indications/severe-to-very-severe-alopecia-areata), severe-to-very-severe alopecia areata with continued twice-monthly dosing, alopecia areata in december of this year, [Moderate to Severe Atopic Dermatitis](https://sec-api.dev/indications/moderate-to-severe-atopic-dermatitis), [Alopecia Areata](https://sec-api.dev/indications/alopecia-areata) |
| Modality |  |
| FDA designations | fast track |

## Timeline

### Oct 2023: trial start

- Status: completed. Date confidence: month. Stage: 2. Indication: moderate-to-severe atopic dermatitis.
- First seen 2025-03-14, last confirmed 2026-08-14.
- SEC Form 10-Q (accession 0001193125-26-349805): "In October 2023, we initiated a Phase 2b clinical study of rezpegaldesleukin in patients with moderate-to-severe atopic dermatitis (the Phase 2b RESOLVE-AD trial), which is ongoing." https://www.sec.gov/Archives/edgar/data/906709/000119312526349805/nktr-20260630.htm
- SEC Form 10-Q (accession 0001193125-26-212596): "In October 2023, we initiated a Phase 2b clinical study of rezpegaldesleukin in patients with moderate-to-severe atopic dermatitis (the Phase 2b RESOLVE-AD trial)." https://www.sec.gov/Archives/edgar/data/906709/000119312526212596/nktr-20260331.htm
- SEC Form 10-K (accession 0001193125-26-104547): "In late October 2023, we initiated a Phase 2b clinical study of rezpegaldesleukin in patients with moderate-to-severe atopic dermatitis (the Phase 2b RESOLVE-AD trial)." https://www.sec.gov/Archives/edgar/data/906709/000119312526104547/nktr-20251231.htm
- SEC Form 10-Q (accession 0001193125-25-270230): "In October 2023, we initiated a Phase 2b clinical study of rezpegaldesleukin in patients with moderate-to-severe atopic dermatitis (the Phase 2b RESOLVE-AD trial)." https://www.sec.gov/Archives/edgar/data/906709/000119312525270230/nktr-20250930.htm
- SEC Form 10-Q (accession 0000950170-25-105275): "In October 2023, we initiated a Phase 2b clinical study of rezpegaldesleukin in patients with moderate-to-severe atopic dermatitis (the Phase 2b RESOLVE-AD trial)." https://www.sec.gov/Archives/edgar/data/906709/000095017025105275/nktr-20250630.htm
- SEC Form 10-Q (accession 0000950170-25-067279): "In October 2023, we initiated a Phase 2b clinical study of rezpegaldesleukin in patients with moderate-to-severe atopic dermatitis, which remains on track for a topline data readout in the first half of 2025." https://www.sec.gov/Archives/edgar/data/906709/000095017025067279/nktr-20250331.htm
- SEC Form 10-K (accession 0000950170-25-039389): "In late October 2023, we initiated a Phase 2b clinical study of rezpegaldesleukin in patients with moderate-to-severe atopic dermatitis, which remains on track for a topline data readout in the first half of 2025." https://www.sec.gov/Archives/edgar/data/906709/000095017025039389/nktr-20241231.htm

### Mar 2024: trial start

- Status: completed. Date confidence: month. Stage: 2. Indication: severe-to-very severe alopecia areata.
- First seen 2025-03-14, last confirmed 2026-08-14.
- SEC Form 10-K (accession 0001193125-26-104547): "In March 2024, we initiated a Phase 2b clinical study of rezpegaldesleukin in patients with severe-to-very severe alopecia areata (the Phase 2b RESOLVE-AA trial)." https://www.sec.gov/Archives/edgar/data/906709/000119312526104547/nktr-20251231.htm
- SEC Form 10-K (accession 0000950170-25-039389): "In March 2024, we initiated a Phase 2b clinical study of rezpegaldesleukin in patients with severe-to-very severe alopecia areata, which remains on track for a topline data readout in the second half of 2025." https://www.sec.gov/Archives/edgar/data/906709/000095017025039389/nktr-20241231.htm
- SEC Form 10-Q (accession 0001193125-26-349805): "In March 2024, we initiated a Phase 2b clinical study in patients with severe-to-very severe alopecia areata (the Phase 2b RESOLVE-AA trial), which is also ongoing." https://www.sec.gov/Archives/edgar/data/906709/000119312526349805/nktr-20260630.htm
- SEC Form 10-Q (accession 0001193125-26-212596): "In March 2024, we initiated a Phase 2b clinical study in patients with severe-to-very severe alopecia areata (the Phase 2b RESOLVE-AA trial)." https://www.sec.gov/Archives/edgar/data/906709/000119312526212596/nktr-20260331.htm
- SEC Form 10-K (accession 0001193125-26-104547): "In March 2024, we initiated a Phase 2b clinical study in patients with severe-to-very severe alopecia areata (the Phase 2b RESOLVE-AA trial)." https://www.sec.gov/Archives/edgar/data/906709/000119312526104547/nktr-20251231.htm
- SEC Form 10-Q (accession 0001193125-25-270230): "In March 2024, we initiated a Phase 2b clinical study in patients with severe-to-very severe alopecia areata (the Phase 2b RESOLVE-AA trial)." https://www.sec.gov/Archives/edgar/data/906709/000119312525270230/nktr-20250930.htm
- SEC Form 10-Q (accession 0000950170-25-105275): "In March 2024, we initiated a Phase 2b clinical study in patients with severe-to-very severe alopecia areata (the Phase 2b RESOLVE-AA trial)." https://www.sec.gov/Archives/edgar/data/906709/000095017025105275/nktr-20250630.htm
- SEC Form 10-Q (accession 0000950170-25-067279): "In March 2024, we initiated a Phase 2b clinical study in patients with severe-to-very severe alopecia areata, which remains on track for a topline data readout in the" https://www.sec.gov/Archives/edgar/data/906709/000095017025067279/nktr-20250331.htm
- SEC Form 10-K (accession 0000950170-25-039389): "In March 2024, we initiated a Phase 2b clinical study in patients with severe-to-very severe alopecia areata, which remains on track for a topline data readout in the second half of 2025." https://www.sec.gov/Archives/edgar/data/906709/000095017025039389/nktr-20241231.htm

### 1H 2025: topline data readout

- Status: scheduled. Date confidence: half. Stage: 2. Indication: moderate-to-severe atopic dermatitis.
- First seen 2025-03-14, last confirmed 2025-05-09.
- SEC Form 10-Q (accession 0000950170-25-067279): "In October 2023, we initiated a Phase 2b clinical study of rezpegaldesleukin in patients with moderate-to-severe atopic dermatitis, which remains on track for a topline data readout in the first half of 2025." https://www.sec.gov/Archives/edgar/data/906709/000095017025067279/nktr-20250331.htm
- SEC Form 10-K (accession 0000950170-25-039389): "In late October 2023, we initiated a Phase 2b clinical study of rezpegaldesleukin in patients with moderate-to-severe atopic dermatitis, which remains on track for a topline data readout in the first half of 2025." https://www.sec.gov/Archives/edgar/data/906709/000095017025039389/nktr-20241231.htm
- SEC Form 10-K (accession 0000950170-25-039389): "The study remains on track for announcement of topline data from the 16-week induction treatment period in the first half of 2025." https://www.sec.gov/Archives/edgar/data/906709/000095017025039389/nktr-20241231.htm

### 2025: trial start

- Status: scheduled. Date confidence: year. Stage: 3.
- First seen 2025-08-08, last confirmed 2025-11-07.
- SEC Form 10-Q (accession 0001193125-25-270230): "As a result of the data from our Phase 2b RESOLVE-AD trial, we expect research and development expense for rezpegaldesleukin for full year 2025 to increase as compared to 2024, as we commence certain activities to support a Phase 3 trial for this program." https://www.sec.gov/Archives/edgar/data/906709/000119312525270230/nktr-20250930.htm
- SEC Form 10-Q (accession 0001193125-25-270230): "We expect research and development expense in total for full year 2025 to increase slightly as compared to 2024, as we commence certain activities to support a Phase 3 trial for rezpegaldesleukin, continue development of NKTR-0165 and initiate research activities for NKTR-0166." https://www.sec.gov/Archives/edgar/data/906709/000119312525270230/nktr-20250930.htm
- SEC Form 10-Q (accession 0000950170-25-105275): "As a result of the data from our Phase 2b RESOLVE-AD trial, we expect research and development expense for rezpegaldesleukin for full year 2025 to increase as compared to 2024, as we commence certain activities to support a Phase 3 trial for this program." https://www.sec.gov/Archives/edgar/data/906709/000095017025105275/nktr-20250630.htm
- SEC Form 10-Q (accession 0000950170-25-105275): "We expect research and development expense in total for full year 2025 to increase as compared to 2024, as we commence certain activities to support a Phase 3 trial for rezpegaldesleukin, continue development of NKTR-0165 and initiate research activities for NKTR-0166." https://www.sec.gov/Archives/edgar/data/906709/000095017025105275/nktr-20250630.htm

### May 6, 2025: primary completion

- Status: completed. Date confidence: exact. Stage: 2. Indication: Moderate to Severe Atopic Dermatitis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06136741 (A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2025-05-06 (ACTUAL); Lead Sponsor Nektar Therapeutics." https://clinicaltrials.gov/study/NCT06136741

### November 26, 2025: primary completion

- Status: completed. Date confidence: exact. Stage: 2. Indication: Alopecia Areata.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06340360 (A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Severe to Very Severe Alopecia Areata in Adult Patients (Rezolve AA)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-11-26 (ACTUAL); Lead Sponsor Nektar Therapeutics." https://clinicaltrials.gov/study/NCT06340360

### Dec 2025: topline data readout

- Status: scheduled. Date confidence: month. Stage: 2. Indication: severe-to-very severe alopecia areata.
- First seen 2025-03-12, last confirmed 2025-11-07.
- SEC Form 8-K (accession 0001213900-25-056909): "The Company expects to report full 52-week data from the RESOLVE-AD trial in early 2026 and expects top-line Phase 2b data for rezpegaldesleukin in alopecia areata in the fourth quarter of 2025." https://www.sec.gov/Archives/edgar/data/906709/000121390025056909/ea0246672-8k_nektar.htm
- Press release filed with the SEC (EX-99) (accession 0001213900-25-056909): "Top-line Phase 2b data for rezpegaldesleukin in alopecia areata expected in Q4 2025" https://www.sec.gov/Archives/edgar/data/906709/000121390025056909/ea024667201ex99-1_nektar.htm
- SEC Form 8-K (accession 0001213900-25-056909): "This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, express or implied statements regarding the Company's plans, progress, and timing relating to the Company's rezpegaldesleukin program in atopic dermatitis, including plans to submit the REZOLVE-AD 16-week induction results for presentation at a medical conference later in 2025 and timing for full 52-week data from the REZOLVE-AD trial, and timing for topline results from the Phase 2b REZOLVE-AA (alopecia areata)" https://www.sec.gov/Archives/edgar/data/906709/000121390025056909/ea0246672-8k_nektar.htm
- SEC Form 10-K (accession 0000950170-25-039389): "In March 2024, we initiated a Phase 2b clinical study of rezpegaldesleukin in patients with severe-to-very severe alopecia areata, which remains on track for a topline data readout in the second half of 2025." https://www.sec.gov/Archives/edgar/data/906709/000095017025039389/nktr-20241231.htm
- Press release filed with the SEC (EX-99) (accession 0001213900-25-023220): ""With enrollment now complete for the atopic dermatitis and alopecia areata Phase 2b trials, we are on track to report topline data for rezpegaldesleukin in the second quarter and in the fourth quarter of this year, respectively." https://www.sec.gov/Archives/edgar/data/906709/000121390025023220/ea023406001ex99-1_nektar.htm
- SEC Form 10-Q (accession 0001193125-25-270230): "We remain on track for a topline data readout from the Phase 2b RESOLVE-AA study in December 2025." https://www.sec.gov/Archives/edgar/data/906709/000119312525270230/nktr-20250930.htm
- SEC Form 10-Q (accession 0000950170-25-105275): "We remain on track for a topline data readout from the Phase 2b RESOLVE-AA study in the second half of 2025." https://www.sec.gov/Archives/edgar/data/906709/000095017025105275/nktr-20250630.htm
- SEC Form 10-K (accession 0000950170-25-039389): "In March 2024, we initiated a Phase 2b clinical study in patients with severe-to-very severe alopecia areata, which remains on track for a topline data readout in the second half of 2025." https://www.sec.gov/Archives/edgar/data/906709/000095017025039389/nktr-20241231.htm
- SEC Form 10-K (accession 0000950170-25-039389): "The study remains on track for announcement of topline data from the 36-week induction treatment period in the second half 2025." https://www.sec.gov/Archives/edgar/data/906709/000095017025039389/nktr-20241231.htm
- Press release filed with the SEC (EX-99) (accession 0001213900-25-041085): ""These data will be followed by the topline data from the Phase 2 study of rezpegaldesleukin in patients with alopecia areata in December of this year." https://www.sec.gov/Archives/edgar/data/906709/000121390025041085/ea0241353ex99-1_nektar.htm

### Apr 2026: topline data readout

- Status: completed, positive. Date confidence: month. Stage: 2. Indication: severe-to-very-severe alopecia areata with continued twice-monthly dosing.
- First seen 2026-08-13, last confirmed 2026-08-13.
- Press release filed with the SEC (EX-99) (accession 0001213900-26-089137): "In April 2026, Nektar announced positive 52-week topline results from the 16-week blinded treatment extension of the Phase 2b REZOLVE-AA study, demonstrating deepening of responses to rezpegaldesleukin in patients with severe-to-very-severe alopecia areata with continued twice-monthly dosing." https://www.sec.gov/Archives/edgar/data/906709/000121390026089137/ea030192901ex99-1.htm

### Q2 2026: trial start

- Status: scheduled. Date confidence: quarter. Stage: 3.
- First seen 2026-02-10, last confirmed 2026-02-10.
- SEC Form 8-K (accession 0001193125-26-043755): "The Company plans to start the Phase 3 trials in the second quarter of 2026." https://www.sec.gov/Archives/edgar/data/906709/000119312526043755/d103279d8k.htm

### Dec 2026: trial start

- Status: scheduled. Date confidence: month.
- First seen 2026-08-14, last confirmed 2026-11-13.
- SEC Form 10-Q (accession 0001193125-26-458868): "We intend to initiate a global registrational trial (ZENITH AA-1) in December 2026 to evaluate rezpegaldesleukin in patients who are 12 years of age or older with severe-to-very-severe alopecia areata." https://www.sec.gov/Archives/edgar/data/906709/000119312526458868/nktr-20260930.htm
- SEC Form 10-Q (accession 0001193125-26-458868): "We intend to initiate a global registrational trial (ZENITH AA-1) in December 2026 to evaluate rezpegaldesleukin in patients who are 12 years of age or older with severe-to-very-severe" https://www.sec.gov/Archives/edgar/data/906709/000119312526458868/nktr-20260930.htm
- SEC Form 10-Q (accession 0001193125-26-349805): "We intend to initiate a global registrational trial (ZENITH-AA-1) in early 2027 to evaluate rezpegaldesleukin in patients who are 12 years of age or older with severe-to-very-severe alopecia areata." https://www.sec.gov/Archives/edgar/data/906709/000119312526349805/nktr-20260630.htm

### mid-2028: interim data readout

- Status: scheduled. Date confidence: half.
- First seen 2026-11-12, last confirmed 2026-11-12.
- Press release filed with the SEC (EX-99) (accession 0001213900-26-118964): "Initial topline data from the ZENITH AD program are expected in mid-2028, with a BLA submission targeted for 2029." https://www.sec.gov/Archives/edgar/data/906709/000121390026118964/ea031199801ex99-1.htm

### May 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Moderate-to-Severe Atopic Dermatitis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07690371 (A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-05 (ESTIMATED); Lead Sponsor Nektar Therapeutics." https://clinicaltrials.gov/study/NCT07690371

### May to Aug 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Moderate-to-Severe Atopic Dermatitis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07690371 (A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-05 (ESTIMATED); Lead Sponsor Nektar Therapeutics." https://clinicaltrials.gov/study/NCT07690371

### June 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Moderate-to-Severe Atopic Dermatitis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07711418 (A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-06 (ESTIMATED); Lead Sponsor Nektar Therapeutics." https://clinicaltrials.gov/study/NCT07711418

### Jun to Sep 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Moderate-to-Severe Atopic Dermatitis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07711418 (A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-06 (ESTIMATED); Lead Sponsor Nektar Therapeutics." https://clinicaltrials.gov/study/NCT07711418

## Same indication

- [ABCL575](https://sec-api.dev/pdufa/abcl575) (ABCL)
- [Amlitelimab](https://sec-api.dev/pdufa/amlitelimab) (SNY)
- [ARQ-234](https://sec-api.dev/pdufa/arq-234) (ARQT)
- [Bempikibart (adx-914)](https://sec-api.dev/pdufa/bempikibart-adx-914) (QTTB)
- [LY4005130](https://sec-api.dev/pdufa/ly4005130) (LLY)
- [Olevaprubart](https://sec-api.dev/pdufa/olevaprubart) (IMA)
- [Litfulo (ritlecitinib tosylate)](https://sec-api.dev/pdufa/ritlecitinib) (PFE)
- [RINVOQ® (upadacitinib)](https://sec-api.dev/pdufa/upadacitinib) (ABBV)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/rezpegaldesleukin.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Rezpegaldesleukin PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/rezpegaldesleukin

```bibtex
@misc{secapidev_pdufa_rezpegaldesleukin_20261116,
  title        = {Rezpegaldesleukin PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/rezpegaldesleukin}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_rezpegaldesleukin_20261116","title":"Rezpegaldesleukin PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/rezpegaldesleukin","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
